Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2017-09-20 Director's Dealing
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2017-09-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a description of an event (FDA clearance of an Investigational New Drug Application) and references an attached press release. There are no financial statements or detailed financial data included. The document is short (3251 characters) and primarily serves as an announcement of a significant corporate event rather than a detailed financial report or other specific filing type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-08-24 English
FORM 10-Q
Interim / Quarterly Report Q2 2017
2017-08-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 1, 2017, reporting the results of the company's annual meeting of stockholders. It details the voting outcomes on director elections, ratification of auditors, and an advisory vote on executive compensation. The content is focused on the official results of shareholder votes at the annual meeting, which matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4131 characters, which is relatively short but contains substantive voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). The document is not a full annual report, audit report, or management report, nor is it a proxy solicitation or remuneration report. Hence, the best classification is DVA with high confidence.
2017-08-02 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 27, 2017, by Titan Pharmaceuticals, Inc. It reports the entry into a material definitive agreement, specifically a venture loan and security agreement providing up to $10 million in loans. It also details the issuance of warrants related to the loan agreement. The content focuses on financing activities, loan terms, and related equity securities issuance. There are no financial statements or comprehensive financial performance data typical of annual or quarterly reports. The document is not a report publication announcement or certification but a current report on a material event. Therefore, it fits the category of Capital/Financing Update (CAP).
2017-07-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the announcement of a Cooperative Research and Development Agreement with research institutes, and includes a press release as an exhibit. There are no financial statements, earnings data, or detailed financial analysis present. The document is relatively short (2552 characters) and serves as a regulatory announcement of a corporate event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2017-07-06 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.